Tag: Halozyme Therapeutics

May 22, 2019 Off

Second development stage target to be used with Halozyme’s Enhanze

Halozyme Therapeutics said Wednesday that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.

January 10, 2019 Off

Halozyme Therapeutics expecting $300M revenue from milestone payments frome Enhanze partnership programs

By Dino Mustafić

The a biotechnology maker of novel oncology and drug-delivery therapies, Halozyme Therapeutics, expects three Enhanze programs to be in phase 3 studies and to have nine active phase 1 programs in addition to its three currently marketed products, by the end of 2019, the company said in an update.